Eton CFO reports 37,000 stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Eton Pharmaceuticals, Inc. Chief Financial Officer Judith M. Matthews filed an initial Form 3 disclosing beneficial ownership of an employee stock option linked to 37,000 shares of common stock at an exercise price of $26.05 per share, expiring on April 12, 2036.
According to the disclosure, these employee stock options will vest in four equal installments on April 13 of 2027, 2028, 2029 and 2030, and are held directly by Matthews.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option | -- | -- | -- |
Footnotes (1)
- F1. The Employee Stock Options will vest in four equal installments on April 13, 2027, 2028, 2029 and 2030.
Key Figures
Key Terms
Employee Stock Option financial
Form 3 regulatory
beneficial ownership financial
vesting financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the ETON Form 3 filed by CFO Judith M. Matthews report?
What is the exercise price and expiration date of the ETON CFO’s stock option?
How do the ETON CFO’s employee stock options vest over time?
Is the ETON CFO’s reported stock option held directly or indirectly?
Does the ETON Form 3 show any stock purchases or sales by the CFO?
AI-generated analysis. How Rhea-AI works. Not financial advice.